More from PubMed

[Magnus1964]

1.

Magnetic resonance imaging (MRI) for local staging before salvage radical prostatectomy: a meta-analysis.

Zapała P, Ślusarczyk A, Rajwa P, Gandaglia G, Zapała Ł, Zattoni F, Lorenc T, Ploussard G, Radziszewski P.

World J Urol. 2023 May;41(5):1275-1284. doi: 10.1007/s00345-023-04383-2. Epub 2023 Apr 5.

PMID: 37019997 Free PMC article. Review.

2.

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.

Chi KN, Fleshner N, Chiuri VE, Van Bruwaene S, Hafron J, McNeel DG, De Porre P, Maul RS, Daksh M, Zhong X, Mason GE, Tutrone RF.

Oncologist. 2023 May 8;28(5):e309-e312. doi: 10.1093/oncolo/oyad008.

PMID: 36994854 Free PMC article. Clinical Trial.

3.

Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews.

Voss T, Krag M, Martiny F, Heleno B, Jørgensen KJ, Brandt Brodersen J.

Cancer Epidemiol. 2023 Jun;84:102352. doi: 10.1016/j.canep.2023.102352. Epub 2023 Mar 22.

PMID: 36963292 Review.

4.

Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected.

Duwe G, Boehm K, Haack M, Sparwasser P, Brandt MP, Mager R, Tsaur I, Haferkamp A, Höfner T.

World J Urol. 2023 May;41(5):1293-1299. doi: 10.1007/s00345-023-04352-9. Epub 2023 Mar 15.

PMID: 36920492 Free PMC article. Clinical Trial.

5.

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.

Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN.

Ann Oncol. 2023 May;34(5):477-485. doi: 10.1016/j.annonc.2023.02.009. Epub 2023 Feb 27.

PMID: 36858151 Clinical Trial.

6.

A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial.

Ilie G, Rendon R, Mason R, MacDonald C, Kucharczyk MJ, Patil N, Bowes D, Bailly G, Bell D, Lawen J, Ha M, Wilke D, Massaro P, Zahavich J, Kephart G, Rutledge RDH.

Eur Urol. 2023 Jun;83(6):561-570. doi: 10.1016/j.eururo.2023.02.009. Epub 2023 Feb 22.

PMID: 36822969 Clinical Trial.

7.

Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.

Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, Tran P, Feng FY.

Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):521-529. doi: 10.1016/j.ijrobp.2022.12.035. Epub 2022 Dec 31.

PMID: 36596347

[maley2711]

and the following nite!!!